norfloxacin has been researched along with Endotoxemia in 5 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Endotoxemia: A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bacterial endotoxemia in patients with cirrhosis induces increased synthesis of nitric oxide that can be corrected with norfloxacin." | 5.08 | Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. ( Chin-Dusting, JP; Dudley, FJ; Jennings, GL; Rasaratnam, B, 1997) |
| " We used antibiotic (norfloxacin) and different probiotic treatments to change the status of gut flora in the cirrhotic rats and evaluated BT, liver function, and endotoxemia in the different models." | 3.76 | Intestinal flora imbalance results in altered bacterial translocation and liver function in rats with experimental cirrhosis. ( Chen, L; Chen, S; Chen, Y; Deng, H; Gao, Z; Gu, Y; Zhang, G; Zhang, W, 2010) |
| "Norfloxacin therapy was not superior to placebo in reducing HVPG (13." | 2.74 | Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. ( Chin-Dusting, J; Colman, J; Kemp, W; Kompa, A; Krum, H; Madan, A; Roberts, S; Thompson, K; Vincent, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 1 |
| Moturi, KR | 1 |
| Wang, L | 1 |
| Zhang, K | 1 |
| Yu, C | 1 |
| Kemp, W | 1 |
| Colman, J | 1 |
| Thompson, K | 1 |
| Madan, A | 1 |
| Vincent, M | 1 |
| Chin-Dusting, J | 2 |
| Kompa, A | 1 |
| Krum, H | 1 |
| Roberts, S | 1 |
| Zhang, W | 1 |
| Gu, Y | 1 |
| Chen, Y | 1 |
| Deng, H | 1 |
| Chen, L | 1 |
| Chen, S | 1 |
| Zhang, G | 1 |
| Gao, Z | 1 |
| Rasaratnam, B | 2 |
| Connelly, N | 1 |
| Chin-Dusting, JP | 1 |
| Jennings, GL | 1 |
| Dudley, FJ | 1 |
1 review available for norfloxacin and Endotoxemia
| Article | Year |
|---|---|
Nitric oxide and the hyperdynamic circulation in cirrhosis: is there a role for selective intestinal decontamination?
Topics: Anti-Bacterial Agents; Bacterial Translocation; Endotoxemia; Humans; Intestines; Liver; Liver Cirrho | 2004 |
2 trials available for norfloxacin and Endotoxemia
| Article | Year |
|---|---|
Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial.
Topics: Anti-Bacterial Agents; Arginine; Cross-Over Studies; Endotoxemia; Humans; Hypertension, Portal; Live | 2009 |
Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis.
Topics: Anti-Infective Agents; Cross-Over Studies; Double-Blind Method; Endotoxemia; Forearm; Humans; Liver | 1997 |
2 other studies available for norfloxacin and Endotoxemia
| Article | Year |
|---|---|
Gut derived-endotoxin contributes to inflammation in severe ischemic acute kidney injury.
Topics: Acute Kidney Injury; Animals; Anti-Bacterial Agents; Bacterial Translocation; Endotoxemia; Endotoxin | 2019 |
Intestinal flora imbalance results in altered bacterial translocation and liver function in rats with experimental cirrhosis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Translocation; Bifidobacterium; Carbon Tetrachloride; Endo | 2010 |